Abstract 1393P
Background
Patients with driver-gene mutations in NSCLC can benefit significantly from corresponding targeted therapy, but respond poorly to immunotherapy (such as EGFR, ALK). As a driver-gene of NSCLC, the relationship between the characteristics of MET and many immune indicators in the Chinese population is still unclear. This study aims to elucidate the characteristics of the MET gene and its relationship with immune indicators in the Chinese NSCLC population.
Methods
732 Formalin-Fixed Paraffin-Embedded (FFPE) lung adenocarcinoma samples were collected and detected by Next Generation Sequencing 603-gene panel from July, 2021 to March, 2023 were selected from the study. The biomarkers of immunotherapy (TMB-High [≥10/Mb], and MMR-related genes (MLH1, MSH2, MSH6, PMS2) were also calculated.
Results
Among the 732 subjects included in the previous detection, a total of 32 cases were detected to carry MET-related mutations. The detection rate of MET gene was 4.37%. The median age was 65 (13-97). 15% of patients belonged to exon 14 skipping type (5/32); MET amplification accounted for the least, accounting for only 6% (2/32 ). The top 3 of mutation frequency were Met_L221W (4/32), MET_Q1067K (2/32), and MET_F206S (2/32). The gene partners of Met co-mutation were analyzed, and the top five genes were PPP2R1A, HIST1H3G, CDKN1B, SYK, and ERBB4. In the analysis of the immune indicators of the MET mutant population and wild-type population, the Mann-Whitney U test found that among the TMB indicators, the mean value of the MET group was 8.09 with SD of 7.91, and the mean value of the un-MET group was 5.94 with SD of 4.98. MET was correlated with TMB with statistical difference (P value 0.02).We also paid attention to MET and MMR-related genes. The analysis showed that there was a significant relationship between MET group and wild-type MET group and MMR gene (p-value: 0.026).
Conclusions
In the Chinese NSCLC population, there is a correlation between MET expression and TMB, and the MET mutation will increase the TMB value. MET expression was significantly correlated with MMR-related gene mutations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1423P - Clinical impact of radiological diagnosis of lymphangitic carcinomatosis in patients with extensive non-small cell lung cancer treated with immunotherapy
Presenter: Anita Bolina
Session: Poster session 20
1424P - Outcome of thromboembolic events and its influence on survival time of advanced NSCLC patients receiving antiangiogenic therapy
Presenter: Wei-Fan Ou
Session: Poster session 20
1425P - Clinical utility of liquid biopsy for the early diagnosis of EGFR mutant advanced lung cancer in real-life setting (CLEAR)
Presenter: Rola El Sayed
Session: Poster session 20
1427P - Exploration of the value of leptomeningeal biopsy in diagnosing and treating non-small cell lung cancer with leptomeningeal metastasis
Presenter: Lin Cai
Session: Poster session 20
1428P - Clinical benefit of combination chemo-immunotherapy in first-line treatment for patients over the age of 65 or 75 with metastatic NSCLC
Presenter: Thierry Landre
Session: Poster session 20
1429P - Homologous recombination repair (HRR) gene mutation: A novel biomarker for precision genomics testing in advanced lung cancer
Presenter: Madhu Nagaraj
Session: Poster session 20
1430P - Excellent performance of a fast and fully-automated RNA based genefusion assay conducted on a large fusion positive non-small cell lung cancer cohort within a multicenter study
Presenter: Arndt Hartmann
Session: Poster session 20
1431P - The nNGM Preclinical Platform: Preclinical research to generate evidence for patients with non-small cell lung cancer harboring variants of unknown significance
Presenter: Martin Ziegler
Session: Poster session 20
1432P - Tumor stage shift in lung cancer during the COVID-19 pandemic: A real-world data study of the Network Oncology Registry
Presenter: Anja Thronicke
Session: Poster session 20